ABSTRACT
TREATMENT OF SCLC Limited Disease Combination chemotherapy with etoposide (VP-16) and cisplatin with concurrent thoracic radiotherapy significantly improves median and 2-year survival. Approximately 60% of patients will have a complete response, and median survival is 12 to 18 months. The 2year survival is about 20% in SCLC, and the 5-year survival rate is about 10%.
